STOCK TITAN

Vertex Pharmaceuticals (VRTX) awards 99.941 deferred stock units to director

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

SACHS BRUCE I reported acquisition or exercise transactions in this Form 4 filing.

Vertex Pharmaceuticals director Bruce I. Sachs received a grant of 99.941 deferred stock units on July 15, 2026 at $475.28 per unit. Each unit represents one share of common stock, payable upon his board service ending, a change of control, disability, or death, bringing his directly held deferred stock units to 15,771.807.

Positive

  • None.

Negative

  • None.
Insider SACHS BRUCE I
Role Director
Type Security Shares Price Value
Grant/Award Deferred Stock Units 99.941 $475.28 $47K
Holdings After Transaction: Deferred Stock Units — 15,771.807 shares (Direct)
Footnotes (1)
  1. [object Object]
Deferred stock units granted 99.941 units Grant to director Bruce I. Sachs on July 15, 2026
Grant price per unit $475.2800 Price per Deferred Stock Unit for the July 15, 2026 award
Deferred stock units after grant 15,771.807 units Directly held Deferred Stock Units by Bruce I. Sachs following the transaction
Underlying common shares per unit 1 share Each deferred stock unit represents one share of Vertex common stock
Underlying common shares for grant 99.941 shares Common stock underlying the 99.941 Deferred Stock Units granted
Deferred Stock Units financial
"Each deferred stock unit represents one share of common stock and is paid out in common stock"
Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.
change of control financial
"upon the earliest to occur of termination of service, a change of control of our company"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.
board of directors financial
"termination of Mr. Sachs' service on our board of directors"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider equity award did Vertex Pharmaceuticals (VRTX) report for Bruce I. Sachs?

Vertex reported that director Bruce I. Sachs received a grant of 99.941 deferred stock units on July 15, 2026 at $475.28 per unit, each representing one share of common stock settled at specified future events.

How many deferred stock units does Bruce I. Sachs now hold at Vertex Pharmaceuticals (VRTX)?

Following the reported grant, Bruce I. Sachs directly holds 15,771.807 deferred stock units. Each deferred stock unit is tied to one share of Vertex common stock and will be paid out in shares when specified service or control events occur.

When will Bruce I. Sachs’s deferred stock units at Vertex (VRTX) be paid out?

The deferred stock units are paid in Vertex common stock upon the earliest of his board service ending, a change of control of the company, or his disability or death, as specified in the footnote to the award.

What type of security was granted to Bruce I. Sachs in the Vertex (VRTX) Form 4?

Bruce I. Sachs received Deferred Stock Units, a derivative security where each unit corresponds to one share of Vertex common stock. The award reflects director compensation rather than an open-market purchase or sale of common shares.

Was the Bruce I. Sachs Vertex (VRTX) Form 4 transaction a market buy or sell?

No. The Form 4 shows an acquisition coded as a grant of Deferred Stock Units, not a market purchase or sale. It represents equity compensation, leaving his directly held deferred stock unit balance at 15,771.807 following the award.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SACHS BRUCE I

(Last)(First)(Middle)
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVE

(Street)
BOSTON MASSACHUSETTS 02210

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Deferred Stock Units(1)07/15/2026A99.941 (1) (1)Common Stock99.941$475.2815,771.807D
Explanation of Responses:
1. Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.
Remarks:
/s/ Christiana Stevenson, Attorney-in-Fact07/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)